Efficacy and safety of TC regimen combined with bevacizumab for advanced ovarian cancer
10.3760/cma.j.cn115355-20231024-00159
- VernacularTitle:TC方案联合贝伐珠单抗治疗晚期卵巢癌的效果及安全性
- Author:
Xiangmei CHEN
1
;
Taifeng LIU
;
Shenghui YAO
Author Information
1. 徐州医科大学附属徐州市立医院肿瘤中心，徐州 221006
- Keywords:
Ovarian neoplasms;
Drug therapy, combination;
Bevacizumab;
Paclitaxel;
Carboplatin
- From:
Cancer Research and Clinic
2024;36(8):610-614
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the efficacy and safety of TC (paclitaxel and carboplatin) regimen combined with bevacizumab in the treatment of advanced ovarian cancer.Methods:A prospective randomized controlled study was conducted. A total of 102 patients with advanced ovarian cancer admitted to Xuzhou Municipal Hospital Affiliated to Xuzhou Medical University from January 2017 to April 2021 were selected and divided into the observation group and the control group according to random number table method, 51 cases in each group. The observation group was treated with TC regimen combined with bevacizumab, and the control group was treated with TC regimen. The clinical efficacy, carbohydrate antigen 125 (CA125) level, human epididymal protein 4 (HE4) level, thymidine kinase 1 (TK1) level, adverse reactions, the overall survival time, recurrence rate and mortality were compared between the 2 groups.Results:There were no statistically significant differences in baseline data such as age, tumor staging and tumor type between the observation group and the control group (all P > 0.05). The effective rate and the disease control rate of the observation group were 58.82% (30/51) and 88.24% (45/51), respectively, which were higher than those of the control group [37.25% (19/51) and 64.71 (33/51)], and the differences were statistically significant ( χ2 = 4.75, P = 0.029; χ2 = 7.85, P = 0.005). Before treatment, there were no statistically significant differences in CA125, HE4 and TK1 levels between the 2 groups (all P > 0.05). After treatment, CA125, HE4 and TK1 levels in the observation group were lower than those in the control group (all P < 0.05). There were no statistically significant differences in the incidence of myelosuppression, liver function damage, gastrointestinal reaction, proteinuria, diarrhea and abdominal pain, high blood pressure between the observation group and the control group (all P > 0.05). The 2-year overall survival rate of the observation group was higher than that of the control group (82.0% vs. 64.7%), while the recurrence rate of the observation group was lower than that of the control group [21.57% (11/51) vs. 45.10% (23/51)], and the differences were statistically significant (all P < 0.05). Conclusions:TC regimen combined with bevacizumab has favorable therapeutic effects and good safety in the treatment of advanced ovarian cancer, which is beneficial to prolong the survival time of patients.
